New hope for older leukemia patients ineligible for harsh chemo
NCT ID NCT03513484
Summary
This early-stage study is testing the safety and best dose of a new drug, nintedanib, when combined with an existing drug, azacitidine. It is for older adults with a specific type of acute myeloid leukemia (AML) who are not candidates for or choose not to have intensive chemotherapy. The goal is to control the cancer and see if the combination is tolerable and effective for this patient group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States
Conditions
Explore the condition pages connected to this study.